Salehi A, Gunnerud U, Muhammed SJ, Ostman E, Holst JJ, Bjrck I, Rorsman P
The study included data from people with a recent history of obesity and excluded those with diabetes or who have been prescribed another Scientists analyzed the data to see how many people developed one of four gastrointestinal conditions pancreatitis, bowel obstruction, gastroparesis, and Researchers found that the participants who took GLP-1 agonists had a little over nine times higher risk of developing pancreatitis, 4.22 times higher risk of having a bowel obstruction, and 3.67 times increased risk for gastroparesis, compared to people who took We are not entirely surprised [by these results]
gelling agent: magnesium salts of fatty acids
(2019) examined the impact of PD medications (levodopa and entacapone) on gut microbiota, finding marked changes in Peptoniphilus, Finegoldia, Faecalibacterium, Fusicatenibacter, Anaerococcus, Bifidobacterium, Enterococcus , and Ruminococcus
GLP-1 receptor agonists mimic natural gut hormones to reduce appetite, slow gastric emptying, and promote gradual weight reduction over 612 months
It has gained attention for its potential role in supporting tissue repair, gastrointestinal health, and overall recovery processes
